Document Detail

Pharmacokinetics of orally administered single- and multiple-dose olopatadine in healthy Chinese subjects: an open-label study.
MedLine Citation:
PMID:  19499962     Owner:  NLM     Status:  MEDLINE    
BACKGROUND AND OBJECTIVES: Olopatadine is a new selective histamine H(1) receptor antagonist with anti-inflammatory and anti-allergic effects. Its pharmacokinetics and safety have not previously been evaluated in Chinese subjects. The aims of this study were to assess the pharmacokinetics and safety of olopatadine after single- and multiple-dose oral administration in healthy Chinese subjects and to identify any differences in pharmacokinetics between males and females. METHODS: The pharmacokinetic parameters for olopatadine in 12 healthy Chinese subjects (six males and six females) were assessed by determining olopatadine concentrations with a validated liquid chromatography-tandem mass spectrometry method. Safety and tolerability were evaluated by monitoring adverse events, laboratory assay results, vital signs, physical examination findings and 12-lead ECG results. RESULTS: The pharmacokinetic parameters (mean +/- SD) for olopatadine following a single dose were: maximum plasma concentration (C(max)) 69.98 +/-20.87 ng/mL, time to reach C(max) (t(max)) 1.02 +/- 0.34 h, elimination half-life (t1/2) 5.87 +/- 4.24 h, area under the plasma-concentration curve (AUC) from time zero to the time of last quantifiable concentration (AUC(last)) 266.00 +/- 143.95 ng.h/mL, AUC from time zero extrapolated to infinity (AUC(infinity)) 283.46 +/- 152.96 ng.h/mL, apparent oral clearance (CL/F) 23.45 +/- 12.59 L/h and apparent volume of distribution after oral administration (V(d)/F) 133.83 +/- 43.07 L. The pharmacokinetic parameters of olopatadine after multiple doses were similar to those after a single dose. In both studies, significantly higher AUC(last), AUC(infinity) and C(max), longer t1/2 (single-dose only) and lower CL/F were observed in female subjects compared with male subjects after both single and multiple dosing. No serious adverse events occurred. CONCLUSION: Olopatadine was shown to be safe and well tolerated in healthy Chinese subjects. There were no changes in absorption and elimination of olopatadine following multiple doses and no accumulation was found. Possible sex-related differences in absorption and elimination of olopatadine were observed.
Nan-Nan Chu; Wei-Li Chen; Hong-Rong Xu; Xue-Ning Li
Publication Detail:
Type:  Comparative Study; Journal Article; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  Clinical drug investigation     Volume:  29     ISSN:  1173-2563     ISO Abbreviation:  Clin Drug Investig     Publication Date:  2009  
Date Detail:
Created Date:  2009-06-08     Completed Date:  2009-08-14     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  9504817     Medline TA:  Clin Drug Investig     Country:  New Zealand    
Other Details:
Languages:  eng     Pagination:  451-7     Citation Subset:  IM    
Department of Clinical Pharmacology, ZhongShan Hospital, Fudan University, Shanghai, China.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Administration, Oral
Anti-Inflammatory Agents, Non-Steroidal / pharmacokinetics*,  pharmacology
Area Under Curve
Asian Continental Ancestry Group
Chromatography, Liquid
Dibenzoxepins / pharmacokinetics*,  pharmacology
Dose-Response Relationship, Drug
Drug Administration Schedule
Sex Factors
Tandem Mass Spectrometry
Young Adult
Reg. No./Substance:
0/Anti-Inflammatory Agents, Non-Steroidal; 0/Dibenzoxepins; 113806-05-6/olopatadine

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Prevalence and characterization of neuropathic pain in a primary-care setting in Spain: a cross-sect...
Next Document:  Effectiveness and tolerability of fixed-dose combination enalapril plus nitrendipine in hypertensive...